Latest news

Bioservo Technologies AB Interim Report January – March 2022 (regulatory information)

Bioservo is investing further in Life Science

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

07 Apr, 2022

Bioservo is investing further in Life Science

During the year, new clinical data will be presented that are expected to demonstrate the positive effects of using Bioservo's grip-strengthening glove Carbonhand. In connection with this, a completely new version of Carbonhand is launched with increased functionality and an improved user experience. To further strengthen the sales organization, we have appointed a Nordic sales manager for Life Science.

Later this year, the final results of the iHand study *, a randomized multicenter study conducted by Roessingh Research and Development in the Netherlands, will be presented. Preliminary data show promising results in terms of the primary power measures, improved hand function and increased grip strength. The final results will be presented at a number of scientific conferences during the year. The first opportunity is during the conference organized by the International Federation of Hand Surgery and Hand Therapy, (IFSSH) in London in June.

In connection with the presentation of the results of the study, Carbonhand 2.0 will be introduced in the Nordic region and the rest of Europe. Carbonhand 2.0 is a completely new version of our grip-strengthening glove, with increased functionality and an improved user experience, which will be able to be used both as an assistive device and in the rehabilitation of patients with impaired hand function.

Carbonhand was launched already in 2013 under the name SEM-Glove and has been available to people with impaired hand function since then, in Sweden mainly via the Swedish Public Employment Service and the Swedish Social Insurance Agency, but also as a prescriptive aid via a few regions. When we are now about to present new clinical data that is expected to strengthen clinical evidence and at the same time introduce a completely new product, we are making a significant investment in Life Science both in the Nordic region and the rest of Europe. Part of this initiative is to strengthen the sales organization with a Nordic sales manager, Philip Simonson, who will work with both direct sales in Sweden and with our Nordic distributors. Philip has extensive experience of sales in medtech and a long experience of working with procurements both within and outside the Swedish market.

Preparations have also been initiated to introduce Carbonhand on the US market at a later stage
"We look forward with confidence to being able to present the final results from the clinical study, where preliminary data show promising results both in terms of improved hand function and increased grip strength." Says Petter Bäckgren, CEO of Bioservo. "Our investment in Life Science is based on the fact that we see great market potential in both Europe and the US, where we with our unique technology have the opportunity to help even more patients to have an increased quality of life."


For more information, please contact:
Petter Bäckgren, CEO
petter.backgren@bioservo.com
+46 8 21 17 10

Mikael Wester, Marketing Director
Mikael.wester@bioservo.com
+46 8 21 17 10


About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North
For more information, please visit www.bioservo.com

* Kottink AIR, Nikamp CDM, Buurke JH, Bos F, van der Sluis CK, van den Broek M, Onneweer B, Stolwijk-Swüste JM, Brink SM, Rietman JS, Prange-Lasonder GB. Six weeks use of a wearable soft-robotic glove during ADL: preliminary results of ongoing clinical study. 5th International Conference on Neurorehabilitation (ICNR), Oct 13-16 2020. The clinical trial has been conducted within the framework of the iHand project. The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 801945.